RLYB Logo

Rallybio Corporation (RLYB) 

NASDAQ
Market Cap
$41.9M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
698 of 776
Rank in Industry
382 of 433

Largest Insider Buys in Sector

RLYB Stock Price History Chart

RLYB Stock Performance

About Rallybio Corporation

Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a …

Insider Activity of Rallybio Corporation

Over the last 12 months, insiders at Rallybio Corporation have bought $0 and sold $0 worth of Rallybio Corporation stock.

On average, over the past 5 years, insiders at Rallybio Corporation have bought $13.11M and sold $5.24M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 5,000 shares for transaction amount of $26,050 was made by Lieber Jonathan I () on 2023‑03‑14.

List of Insider Buy and Sell Transactions, Rallybio Corporation

2023-03-14Purchase
5,000
0.0123%
$5.21$26,050-13.69%
2023-03-07Saledirector
100,000
0.242%
$8.20$820,000-44.54%
2023-03-07Sale10 percent owner
100,000
0.242%
$8.20$820,000-44.54%
2022-06-03Sale
99,671
0.4398%
$12.50$1.25M-23.70%
2022-06-03Sale
99,671
0.4398%
$12.50$1.25M-23.70%
2022-05-23Sale
33,553
0.1126%
$13.00$436,189-43.36%
2022-05-23Sale
33,553
0.1126%
$13.00$436,189-43.36%
2022-03-21PurchaseSee Remarks
3,000
0.0103%
$8.04$24,120+4.79%
2022-02-08Saledirector
210,000
0.6366%
$13.05$2.74M-36.62%
2022-02-08Sale10 percent owner
210,000
0.6366%
$13.05$2.74M-36.62%
2022-01-19PurchaseSee Remarks
1,400
0.0046%
$8.70$12,180+7.49%
2022-01-13PurchaseSee Remarks
5,000
0.0172%
$9.15$45,752+6.63%
2022-01-12PurchaseSee Remarks
5,000
0.0176%
$10.55$52,750-5.66%
2022-01-11PurchaseChief Executive Officer
4,496
0.0146%
$10.65$47,882-13.16%
2022-01-10PurchaseChief Executive Officer
5,504
0.0172%
$10.10$55,590-11.65%
2022-01-07PurchaseSee Remarks
10,000
0.0313%
$9.41$94,069-4.69%
2021-08-02Purchasedirector
76,923
0.2018%
$13.00$999,999-39.61%
2021-08-02Purchasedirector
307,692
0.8073%
$13.00$4M-39.61%
2021-08-02Purchasedirector
576,923
1.5136%
$13.00$7.5M-39.61%
2021-08-02Purchasedirector
615,384
1.6145%
$13.00$8M-39.61%

Insider Historical Profitability

<0.0001%
VIKING GLOBAL INVESTORS LP10 percent owner
4194777
10.1109%
$1.0110<0.0001%
SHANNON TIMOTHY Mdirector
2409712
5.8083%
$1.0110<0.0001%
PARMAR KUSHdirector
2378969
5.7342%
$1.0114<0.0001%
HUNT RONALDdirector
2301603
5.5477%
$1.0110<0.0001%
Hopfner Robert Lornedirector
2267411
5.4653%
$1.0110<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Viking Global Investors$7.76M10.124.19M0%+$0<0.01
5Am Venture Management Llc$6.72M8.763.63M0%+$00.45
New Leaf Venture Partners$6.11M7.973.3M0%+$05.82
Tpg Gp A Llc$5.6M7.313.03M0%+$00.11
Pivotal Bioventure Partners Investment Advisor Llc$4.45M5.82.4M0%+$03.58
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.